key: cord-0846702-ko9irio2
authors: Ren, Jianjun; Pang, Wendu; Luo, Yaxin; Cheng, Danni; Qiu, Ke; Rao, Yufang; Zheng, Yongbo; Dong, Yijun; Peng, Jiajia; Hu, Yao; Ying, Zhiye; Yu, Haopeng; Zeng, Xiaoxi; Zong, Zhiyong; Liu, Geoffrey; Wang, Deyun; Wang, Gang; Zhang, Wei; Xu, Wei; Zhao, Yu
title: Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization and Mortality
date: 2021-10-30
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.10.049
sha: b3b975d9bce45ca126914ecd6d32a4c4901fc50c
doc_id: 846702
cord_uid: ko9irio2

Background It remains unclear if patients with AR and/or asthma are susceptible to COVID-19 infection, severity and mortality. Objective To investigate the role of AR and/or asthma in COVID-19 infection, severity, and mortality, and assess whether long-term AR and/or asthma medications affected the outcomes of COVID-19. Methods Demographic and clinical data of 70,557 adult participants completed SARS-Cov-2 testing between March 16 and December 31, 2020 in the UK Biobank were analyzed. The rates of COVID-19 infection, hospitalization and mortality in relation to preexisting AR and/or asthma were assessed based on adjusted generalized linear models. We further analyzed the impact of long-term AR and/or asthma medications on the risk of COVID-19 hospitalization and mortality. Results AR patients of all ages had lower positive rates of SARS-Cov-2 tests (RR:0.75, 95% CI: 0.69-0.81, p<0.001), with lower susceptibility in males (RR: 0.74, 95%CI: 0.65-0.85, p<0.001) than females (RR: 0.8, 95% CI: 0.72-0.9, p<0.001). However, similar effects of asthma against COVID-19 hospitalization were only major in participants aged <65 (RR:0.93, 95% CI: 0.86-1, p=0.044) instead of elderlies. In contrast, asthma patients tested positively had higher risk of hospitalization (RR:1.42, 95% CI: 1.32-1.54, p<0.001). Neither AR nor asthma had impact on COVID-19 mortality. None of conventional medications for AR or asthma, e.g., antihistamines, corticosteroids or β2 adrenoceptor agonists showed association with COVID-19 infection or severity. Conclusion AR (all ages) and asthma (aged<65) act as protective factors against COVID-19 infection, while asthma increase risk for COVID-19 hospitalization. None of the long-term medications had significant association with infection, severity and mortality of COVID-19 among patients with AR and/or asthma.

Standard deviation (SD) 103 Relative risks (RRs) 104 Confidence intervals (CIs) 105 Angiotensin-converting enzyme 2 (ACE2) How does this study impact current management guidelines 117 We provided new insights on the association between allergic diseases and COVID-19 118 prevalence and outcomes. We suggested more attention should be paid to the education and Introduction 122 The emergence of COVID-19 has had a huge impact on population health globally. As of 123 May 9 th , 2021, there have been more than 157 million confirmed COVID-19 cases worldwide 124 and over 3.2 million deaths were attributed to the pandemic (https://covid19.who.int./). It has 125 been reported that some underlying diseases such as dementia, pneumonia, depression, diabetes, 126 atrial fibrillation, chronic obstructive pulmonary disease (COPD) and hypertension [1] , as well 127 as high cytokine, lactate dehydrogenase level [2] and ages could affect the prevalence and 128 outcomes of COVID-19. 129 Allergic rhinitis (AR) and asthma are common and underestimated respiratory diseases 130 and often simultaneously occur as united airway disease [3] [4] [5] . Whether AR and asthma acting as 131 independent risk factor for the infection, hospitalization and mortality of COVID-19 remains 132 controversial. It was reported that AR/asthma patients were often exacerbated by viral 133 respiratory infections [6, 7] . A Korean nationwide cohort study reported that AR and asthma 134 increased the susceptibility and severity of COVID-19 [8] . On the contrary, other reports 135 suggested that asthma did not pose a threat to the diagnosis and severity of COVID-19 [9] [10] [11] [12] . 136 Moreover, some meta-analyses even concluded that asthma was considered as an independent 137 protective factor for the death of patients with COVID-19 [13] [14] [15] .

Our current study aimed to explore the role of AR and/or asthma in the risk of infection, 139 severity and mortality of COVID-19 based on a large prospective cohort in UK Biobank, and 140 to evaluate whether long-term medications for AR and/or asthma would affect the clinical 141 manifestation and outcomes of COVID-19. England were examined. We excluded individuals with 1) who died before the pandemic (set 155 as February 1 st , 2020); 2) whose location belonged to UKB assessment centers in Scotland and 156 Wales (where no SARS-CoV-2 testing data were available); and 3) who were diagnosed with Medication data of UK Biobank participants were available from a verbal interview by a 164 trained nurse on prescription medications including type and number of medications. The long-165 term medications were defined as regular medications taken weekly and monthly, as opposed 166 to the short-term medications. We summarized different types of medications such as 167 antihistamine, glucocorticoids, inhaled corticosteroids (ICS) and β2 adrenoceptor agonists 168 according to their coding in Table E1 . Medication analyses were conducted for participants who had either AR or asthma, and 216 participants who had AR or asthma but never used those medicines served as the controls in 217 corresponding analysis.

For subgroup analyses, Model**** was constructed for participants stratified by gender 219 (female or male), age (< 65 or ≥65 years old), BMI (≤30 or >30), ethnic background (white 220 or non-white) and smoking (never, previous or current). Preexisting dementia was reported to 221 be associated with dramatically increasing risk of COVID-19 hospitalization and death (OR = 222 7.30) [1] due to the APOE e4 genotype [19] , hence sensitivity analysis was conducted for 223 participants without dementia to assess the robustness of our results.

In order to conduct a more in-depth analysis for asthma, asthma participants were further 225 divided into allergic asthma and non-allergic asthma groups, and the Model**** was applied for the sub-analysis. Allergic asthma was defined as asthma with any allergic disease (hayfever, 227 allergy rhinitis or eczema, defined as ICD-10 codes: L20 and J30.1-J30.4 or self-report in 228 questionnaires) [10] , and non-allergic asthma referred to asthma without any allergic disease. The 229 reference was healthy control group without asthma or allergic diseases. In another sub-230 analysis, we explored the differences in the outcomes of COVID-19 between asthma patients 231 with/without COPD (COPD was defined as the following ICD-10 codes: J43, J44 or self-232 report in questionnaires) and participants without asthma or COPD (reference group).

All analyses were performed by R 3.6.3 (R Development Core Team, Vienna, Austria), and 234 P < 0.05 was considered for statistical significance. As shown in Table 1 and Table E2 , there were 70,557 participants tested SARS-CoV-2, were more likely to occur in the older participants than the younger, respectively. The effect of AR and asthma on the severity and mortality of COVID-19 258 As shown in Table 2 The effects of long-term medications for AR and/or asthma on infection, hospitalization 266 and mortality of COVID-19. 267 We summarized four main long-term medication types that patients commonly used for 268 control symptoms of AR or asthma, including β2 adrenoceptor agonists, antihistamine, 269 systemic glucocorticoids, and corticosteroid nasal sprays (CNS). As shown in Table 3 and 

We further compared the differences in COVID-19 infection/outcomes between patients 296 with allergic and non-allergic asthma (Table E8 ) and between asthma patients with and without 297 COPD (Table E9) , respectively. No significant difference between allergic and non-allergic Some studies have shown that dementia had a striking association with COVID-19 related 306 hospitalizations and deaths [1] . We therefore performed sensitivity analyses by excluding 307 participants with preexisting dementia (n=1,876) to evaluate the robustness of our results 308 (Table E10) . We observed consistent results that participants with AR (with/without asthma) We consider the reason why patients with AR (of all ages) or asthma (among younger 326 participants) were associated with lower positive rate of SARS-CoV-2 test results. Angiotensin-327 converting enzyme 2 (ACE2) is the receptor for the attachment and entry of SARS-CoV-2 into 328 the host cells [20] . It has been reported that allergen provocation of respiratory tract would induce 329 allergic airway inflammation which resulted in a decrease of ACE-2 expression, indicating that 330 allergic inflammation may of great relevance to reduce the risk of COVID-19 infection [11, 21, 22] .

In addition, allergen-specific T cells may recruit a faster and more efficient memory-type 332 response to deal with heterologous SARS-CoV-2 epitopes, which may provide significant 333 advantages for patients with allergic diseases [23, 24] . However, this protective effect of asthma on COVID-19 infection was mainly observed in patients who were younger than 65 years in 335 our study. The exact reason is unclear but we speculated that it might attribute to the decline in 336 lung function and immunity with age [25] , which could lead to poorer prognoses [26, 27] . 337 It is interesting that AR and asthma exhibited distinct effects on COVID-19 hospitalization 338 in our study, of which asthma was a risk factor while the influence of AR was not statistically 339 notable. One potential reason is that SARS-CoV-2 impacts the lung parenchyma, so the study and revealed that compared with patients without asthma, asthma patients with COVID-19 were more likely to receive critical care during hospitalization [32] . Several independent 356 studies have observed a potential association between asthma phenotypes and COVID-19-357 related outcomes. According to the results of Zhu et al., nonallergic asthma was significantly 358 associated with severe COVID-19, while allergic asthma had no statistically significant 359 association with severe COVID-19. They also reported that this significant association 360 persisted regardless of whether asthma patients had COPD or not [10] . However, we did not 361 observe such differences between allergic and non-allergic rhinitis. Although our research data 362 came from the same UK Biobank database, the confounders we adjusted for and the 363 populations we included were different. In our current study, we excluded participants who did 364 not have SARS-cov-2 testing results, while these participants were considered as SARS-cov-2 365 negative in their study.

Another English cohort study (QResearch database) reported that COVID-19 patients with 367 COPD or asthma had an increased risk of hospitalization and death [33] . However, our results 368 did not observe such trends, mainly due to the different population cohort we studied. Another 

Although the advent of our study provided new insights into the association between 383 allergic diseases and the prevalence and outcomes of COVID-19, a few limitations still existed.

First, the UKB may have a healthy volunteer selection bias in participants subgroups who were 385 older, female, or lived in less socioeconomically deprived areas [39] . Second, the sample size for 386 assessing COVID-19 related mortality in AR/asthma patients who had taken long-term about their own COVID-19 exposures or more afraid to present with COVID-19-like 399 symptoms, and therefore were more likely to wear masks or adhere to social distancing.

In summary, AR (in all ages) is associated with lower rates of COVID-19 infection, but 401 not with the severity and mortality of COVID-19. Similar protective effect in asthma patients, 402 whatever allergic asthma or non-allergic asthma is observed only in those aged less than 65 403 years, but not in the elderlies (aged 65 years). In asthmatic patients with confirmed COVID-404 19, there is a higher risk of hospitalization than healthy controls. 

Preexisting open access resource for identifying the causes of a wide range of complex diseases 447 of middle and old age

Suppressants on the Risk of COVID-19: A Propensity Score-Matched Study Using UK 450

Tobacco Smoking and Risk for Pulmonary Fibrosis: 452 A Prospective Cohort Study from the UK Biobank

Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort

Coronavirus disease 2019 457 and asthma, allergic rhinitis: molecular mechanisms and host-environmental 458 interactions

Distinct effects of asthma and 460 COPD comorbidity on disease expression and outcome in patients with COVID-19

Type 2 463 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells

Asthma-associated risk for COVID-466 19 development

Targets 468 of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease

Immunologic mechanisms in 471 asthma

Relationship 473 between age and bronchodilator response at diagnosis in adult-onset asthma

Incidence 476 and remission of asthma: a retrospective study on the natural history

Risk of adverse outcomes in patients with underlying respiratory conditions admitted 491 to hospital with COVID-19: a national, multicentre prospective cohort study using 492 the ISARIC WHO Clinical Characterisation Protocol UK

Association 495 between pre-existing respiratory disease and its treatment, and severe COVID-19: a 496 population cohort study

Chronic Respiratory Diseases 498 and the Outcomes of COVID-19: A Nationwide Retrospective Cohort Study of 39,420 Cases

Inhibitory 501 effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E

replication and cytokine production by primary cultures of human nasal and tracheal 503 epithelial cells

Inhaled corticosteroids and COVID-19: a systematic 505 review and clinical perspective

Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral 508

Replication-Transcription Complex in Cultured Cells

COVID-19-related death among patients with chronic obstructive pulmonary disease or 511 asthma prescribed inhaled corticosteroids: an observational cohort study using the 512 OpenSAFELY platform

Comparison 514 of Sociodemographic and Health-Related Characteristics of UK Biobank Participants 515

With Those of the General Population

J o u r n a l P r e -p r o o f Table 2 

Model****: